Risk factors for fingolimod-induced lymphopenia in multiple sclerosis

BACKGROUND: Lymphopenia is a well-known adverse event of fingolimod, a disease-modifying drug for multiple sclerosis (MS). OBJECTIVES: The objective of this paper is to investigate risk factors for predicting fingolimod-induced lymphopenia in MS by frequent hematological monitoring. METHODS: We retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohtani, Ryohei, Mori, Masahiro, Uchida, Tomohiko, Uzawa, Akiyuki, Masuda, Hiroki, Liu, Jia, Kuwabara, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824911/
https://www.ncbi.nlm.nih.gov/pubmed/29497558
http://dx.doi.org/10.1177/2055217318759692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824911/
https://www.ncbi.nlm.nih.gov/pubmed/29497558
http://dx.doi.org/10.1177/2055217318759692

Ejemplares similares